[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Emanuel P, Wang B, Wu M, Burstein DE: p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol; 2005 May;18(5):645-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma.
  • Morphologic distinction of high-grade adenoid cystic carcinoma from basaloid squamous cell carcinoma can be difficult.
  • We have investigated the possibility that immunohistochemical staining for the presence of p63, a novel epithelial stem-cell regulatory protein, could be a useful means of distinguishing these two neoplasms.
  • Archival, routinely processed slides were subjected to citrate-based antigen retrieval, exposure to anti-p63 monoclonal 4A4, and developed with a streptavidin-biotin kit and diaminobenzidine as chromogen. p63 was detected in 100% of the adenoid cystic carcinomas (n=14) and 100% of basaloid squamous cell carcinomas (n=16).
  • Basaloid squamous cell carcinomas consistently displayed diffuse p63 positivity, with staining of nearly 100% of tumor cells.
  • In contrast, adenoid cystic carcinoma displayed a consistently compartmentalized pattern within tumor nests.
  • (1) selective staining of a single peripheral layer of p63-positive cells surrounding centrally located tumor cells that were p63-negative and (2) tumor nests consisting of multiple contiguous glandular/cribriform-like units of p63-positive cells surrounding or interspersed with p63-negative cells. p63 immunostaining constitutes a specific and accurate means of distinguishing adenoid cystic carcinoma from basaloid squamous cell carcinoma. p63 positivity in adenoid cystic carcinoma appears to be homologous to that seen in the basal and/or myoepithelial compartments of salivary gland and other epithelia, and may signify a stem-cell-like role for these peripheral cells.
  • Diffuse p63 positivity in basaloid squamous cell carcinoma suggests dysregulation of p63-positive stem cells in poorly differentiated squamous carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Phosphoproteins / analysis. Trans-Activators / analysis
  • [MeSH-minor] DNA-Binding Proteins. Diagnosis, Differential. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15529180.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


2. De Dosso S, Mazzucchelli L, Ghielmini M, Saletti P: Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. Tumori; 2009 May-Jun;95(3):378-81
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma.
  • Esophageal localization of adenoid cystic carcinoma of minor salivary glands is rare; it may occur in the early to mid-sixties' age group and is more frequently encountered in men than women.
  • In the majority of cases, it arises from subepithelial glands of the middle to lower third of the esophagus, a similar distribution as squamous cell carcinoma.
  • We report a case of a patient with metastatic primary esophageal adenoid cystic carcinoma progressing on platinum- and irinotecan-based regimens, who achieved an objective response with oxaliplatin-based chemotherapy in combination with cetuximab.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / secondary. Esophageal Neoplasms / pathology. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / secondary

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688981.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


3. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication.
  • The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


Advertisement
4. Yu Y, Baras AS, Shirasuna K, Frierson HF Jr, Moskaluk CA: Concurrent loss of heterozygosity and copy number analysis in adenoid cystic carcinoma by SNP genotyping arrays. Lab Invest; 2007 May;87(5):430-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent loss of heterozygosity and copy number analysis in adenoid cystic carcinoma by SNP genotyping arrays.
  • Adenoid cystic carcinoma (ACC) is one of the most common malignancies to arise in the salivary glands, yet very little is known of the genetic alterations that are involved in the pathogenesis of this disease.
  • To further examine the genetic changes that underlie ACC, we analyzed genomic DNA obtained from 22 primary ACC and two ACC-derived cell lines by high-density oligonucleotide single-nucleotide polymorphism genotyping arrays (Affymetrix GeneChip Human Mapping 100K Set).
  • This is in contrast to a much higher rate of genomic alterations detected in a cohort of squamous carcinomas analyzed by the same methods.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. DNA Mutational Analysis / methods. Gene Dosage. Loss of Heterozygosity. Polymorphism, Single Nucleotide / genetics. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Chromosome Deletion. DNA, Neoplasm / analysis. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Microsatellite Repeats. Middle Aged. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372589.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / R01DE04694
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


5. Ben-Izhak O, Laster Z, Araidy S, Nagler RM: TUNEL - an efficient prognosis predictor of salivary malignancies. Br J Cancer; 2007 Apr 10;96(7):1101-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TUNEL - an efficient prognosis predictor of salivary malignancies.
  • Biological markers are necessary for predicting prognosis of salivary malignancies and better understanding the pathogenesis of salivary cancer.
  • We analysed terminal deoxynucleotidyl transferase (TdT)-mediated biotinylated deoxyuridine-triphosphate (dUTP)-biotin nick-end labelling (TUNEL), p53 and Ki67 expression in 66 patients with malignant salivary tumours by immonohistochemistry, and correlated the data with survival, disease-free survival, tumour grade, stage, and local and distant metastasis.
  • TUNEL efficiently predicted poor prognosis in salivary malignancies.
  • The correlation between TUNEL, p53 and Ki67 staining and survival probabilities, and the pathological grade, stage and metastasis spread of salivary malignancies makes this a highly effective tool in patient follow-up and prognosis.
  • [MeSH-major] Apoptosis. In Situ Nick-End Labeling. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Predictive Value of Tests. Prognosis. Survival Rate. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Annu. 1987;22 Pt 1:1-53 [3033585.001]
  • [Cites] Laryngoscope. 1986 Oct;96(10):1139-44 [3762288.001]
  • [Cites] Mol Cell Biol. 1988 Feb;8(2):531-9 [2832726.001]
  • [Cites] J Laryngol Otol. 1989 Oct;103(10):939-44 [2685148.001]
  • [Cites] Oncology (Williston Park). 1989 Feb;3(2):47-56; discussion 56, 58, 62 [2701410.001]
  • [Cites] Oncology (Williston Park). 1989 Mar;3(3):85-91; discussion 94, 99 [2701414.001]
  • [Cites] Curr Opin Oncol. 1990 Jun;2(3):589-95 [2092779.001]
  • [Cites] Hepatology. 1995 May;21(5):1465-8 [7737654.001]
  • [Cites] Methods Cell Biol. 1995;46:29-39 [7541886.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3693-701 [8758936.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • [Cites] Histopathology. 1998 Jan;32(1):28-34 [9522213.001]
  • [Cites] Histopathology. 1998 Sep;33(3):240-7 [9777390.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1018-25 [10091783.001]
  • [Cites] Oncology. 1999 Apr;56(3):239-47 [10202280.001]
  • [Cites] Histopathology. 1999 Mar;34(3):241-9 [10217565.001]
  • [Cites] Adv Anat Pathol. 1999 May;6(3):140-8 [10342011.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:34-7 [10466759.001]
  • [Cites] Hum Pathol. 1999 Sep;30(9):1097-105 [10492046.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):913-20 [10491515.001]
  • [Cites] Oral Dis. 1999 Apr;5(2):117-22 [10522207.001]
  • [Cites] Magy Onkol. 2004;48(4):309-13 [15655576.001]
  • [Cites] Histopathology. 2006 May;48(6):674-82 [16681683.001]
  • [Cites] Pathol Res Pract. 2000;196(3):167-74 [10729921.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1213-9 [10810424.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):175-82 [10981868.001]
  • [Cites] Ann Urol (Paris). 2000 Aug;34(4):236-9 [10994142.001]
  • [Cites] Histopathology. 2001 Nov;39(5):469-75 [11737304.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):371-5 [12385580.001]
  • [Cites] Histopathology. 2002 Dec;41(6):519-25 [12460204.001]
  • [Cites] J Pathol. 2003 Jan;199(1):90-7 [12474231.001]
  • [Cites] Oncology. 2003;64(4):389-98 [12759537.001]
  • [Cites] J Urol. 2003 Jul;170(1):241-5 [12796697.001]
  • [Cites] Cancer. 1971 Jun;27(6):1415-8 [4325986.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1980 Mar;49(3):229-32 [6928307.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Nov-Dec;9(2):82-92 [3623942.001]
  • (PMID = 17325701.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2360125
  •  go-up   go-down


6. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major salivary gland diseases. Multicentre study.
  • Malignant tumours instead were fewer in number compared to the literature (14% vs 25-30%); the most frequent being mucoepidermoid carcinoma (18.2%) of which 44% G1, 33% G2 and 23% G3.
  • Adenoid-cystic carcinoma was observed in 15.3% and < or = 10% for all the other most frequent histological malignant neoplasms.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • Finally, mucoepidermoid carcinoma tumours showed best survival, followed by adenoid-cystic carcinoma with ranges, respectively, 83 and 81.
  • [MeSH-major] Salivary Gland Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


7. Sasahira T, Oue N, Kirita T, Luo Y, Bhawal UK, Fujii K, Yasui W, Kuniyasu H: Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. Histopathology; 2008 Dec;53(6):667-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland.
  • The aim was to examine Reg IV expression in adenoid cystic carcinomas (ACCs) in salivary glands.
  • Reg IV was expressed by salivary duct epithelia and acinus myoepithelia, but not in squamous epithelia.
  • Reg IV expression was found in 41% (17/41) of ACCs, but in none of 40 oral squamous cell carcinomas (OSCCs) and was associated with nodal metastasis (P = 0.047) and poor prognosis (P = 0.012) in ACCs.
  • Cell growth was inhibited by AS treatment in Reg IV+ ACC3 cells, but not in HSC-4 OSCC cells, whereas in vitro invasion of neither cell types was affected by AS treatment.
  • CONCLUSIONS: These results suggest that Reg IV might accelerate cell growth and disease progression of ACCs.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Lectins, C-Type / metabolism. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology
  • [MeSH-minor] Aged. Cell Line, Tumor. Cell Proliferation. Disease Progression. Disease-Free Survival. Humans. Immunohistochemistry. Mucin-2 / metabolism. Phosphorylation. Prognosis. Receptor, Epidermal Growth Factor / metabolism


8. Chetty R, Serra S, Hsieh E: Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant. Am J Surg Pathol; 2005 Dec;29(12):1668-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant.
  • Two cases of a distinctive variety of basaloid squamous carcinoma (BSC) of the anal canal are described.
  • Accompanying dysplasia of the overlying squamous mucosa was absent.
  • This appearance together with microcystic spaces simulated that of an adenoid cystic carcinoma.
  • BSC of the anal canal with an adenoid cystic pattern is an infrequently encountered and reported variant, although it is seen more often in the aerodigestive tract.
  • There may be an increased propensity for BSC with an adenoid cystic pattern to metastasize to the liver, but the number of cases encountered are too small to be definitive.
  • The histologic differential diagnosis is true salivary gland-type adenoid cystic carcinoma and basal cell adenocarcinoma.
  • Immunohistochemistry and awareness of this unusual pattern of BSC will facilitate the correct diagnosis being reached.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Basosquamous / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cisplatin / therapeutic use. DNA-Binding Proteins. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Mitomycin / therapeutic use. Phosphoproteins / metabolism. Radiotherapy. Time Factors. Trans-Activators / metabolism. Transcription Factors. Treatment Outcome. Tumor Burden. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327441.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 50SG953SK6 / Mitomycin; 68238-35-7 / Keratins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Maruyama S, Cheng J, Yamazaki M, Zhou XJ, Zhang ZY, He RG, Saku T: Metastasis-associated genes in oral squamous cell carcinoma and salivary adenoid cystic carcinoma: a differential DNA chip analysis between metastatic and nonmetastatic cell systems. Cancer Genet Cytogenet; 2010 Jan 1;196(1):14-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis-associated genes in oral squamous cell carcinoma and salivary adenoid cystic carcinoma: a differential DNA chip analysis between metastatic and nonmetastatic cell systems.
  • Overall modes of differential gene expressions were analyzed between human oral/salivary carcinoma cell systems with (MK-1 and ACCM) and without (ZK-1/ZK-2 and ACC2/ACC3) metastatic potential by using micro-array analysis with cancer-associated DNA chips to determine the kinds of genes associated with metastatic behaviors.
  • MK-1 and/or ACCM showed lower levels of gene expression in extracellular matrix-related molecules, such as collagen type IV, laminin, and adhesion molecules such as cadherin 2, but higher levels of genes which control extracellular matrix degradation, such as MMP 9, as well as cell growth and cycle, such as FGF7 and cyclin D1.
  • Metastatic potentials of oral/salivary carcinoma cells seem to have resulted from certain combinations of over-/underexpression of the genes, which were responsible for extracellular matrix metabolism and cell growth in particular.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Neoplasm Metastasis / genetics. Oligonucleotide Array Sequence Analysis. Salivary Gland Neoplasms / genetics


10. Meer S, Altini M: CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology; 2007 Jul;51(1):26-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia.
  • AIMS: To evaluate cytokeratin (CK) 7/20 expression patterns in salivary gland neoplasia.
  • METHODS AND RESULTS: Formalin-fixed paraffin embedded tissue from 153 salivary gland tumours were evaluated for CK7/20 immunoreactivity.
  • The tumours included pleomorphic adenoma (n = 24), myoepithelioma (n = 9), papillary cystadenoma (n = 3), oncocytoma (n = 2), adenoid cystic carcinoma (n = 22), mucoepidermoid carcinoma (n = 21), polymorphous low-grade adenocarcinoma (n = 21), carcinoma ex-pleomorphic adenoma (n = 11), acinic cell carcinoma (n = 17), epimyoepithelial carcinoma (n = 7), oncocytic carcinoma (n = 3), hyalinizing clear cell carcinoma (n = 1), papillary cystadenocarcinoma (n = 1), salivary duct carcinoma (n = 3), adenocarcinoma (not otherwise specified) (n = 4) and squamous carcinoma (n = 4).
  • All salivary gland neoplasms showed a CK7+/CK20- immunoprofile ranging from 5 to 100%.
  • Squamous carcinoma showed negative CK7/20 immunoexpression.
  • CONCLUSIONS: Although the CK7/20 immunoprofile is not useful in distinguishing the various types of salivary gland neoplasms or between benign and malignant salivary gland tumours, it may facilitate differentiation of primary salivary gland neoplasia from metastatic tumours and squamous carcinoma, and the diagnosis of metastatic salivary gland tumours.
  • [MeSH-major] Gene Expression Profiling. Keratin-20 / metabolism. Keratin-7 / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Salivary Glands / metabolism. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593078.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


11. Kouzu Y, Uzawa K, Kato M, Higo M, Nimura Y, Harada K, Numata T, Seki N, Sato M, Tanzawa H: WISP-2 expression in human salivary gland tumors. Int J Mol Med; 2006 Apr;17(4):567-73
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WISP-2 expression in human salivary gland tumors.
  • This study was designed to disclose detailed genetic mechanisms in salivary gland tumors (SGTs) for development of novel independent marker.
  • We constructed an in-house cDNA microarray carrying 2,201 cDNA clones derived from SGT and oral squamous cell carcinoma cDNA libraries.
  • Four cell lines that originated from the SGT-derived cell lines were analyzed using this microarray system.
  • The genes identified by our microarray system were further analyzed at the mRNA or protein expression level in other types of human cancer cell lines and clinical samples (ten normal salivary glands [NSGs], eleven pleomorphic adenomas, ten adenoid cystic carcinomas and three adenocarcinomas).
  • We found a higher expression of the WISP-2 gene in the SGT-derived cell lines compared with other types of human cancer cell lines.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Intercellular Signaling Peptides and Proteins / genetics. Neoplasm Proteins / genetics. Salivary Gland Neoplasms / genetics. Transcription Factors / genetics
  • [MeSH-minor] CCN Intercellular Signaling Proteins. Cell Line, Tumor. Gene Library. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis / methods. RNA, Messenger / genetics. RNA, Messenger / metabolism. Repressor Proteins. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525711.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP2 protein, human
  •  go-up   go-down


12. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, Barbatis C: Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol; 2006 Apr;120(4):298-304
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours.
  • OBJECTIVES: To investigate the topography of E-cadherin and its possible correlation with the histological phenotype of salivary gland tumours.
  • MATERIAL AND METHODS: Archival formalin-fixed, paraffin-embedded sections of 54 benign and 56 malignant tumours and 24 samples of normal and inflamed salivary gland tissue were studied immunohistochemically using an Envision/horseraddish peroxidase (HRP) technique.
  • RESULTS: In normal and inflamed salivary gland samples, E-cadherin was expressed at the membrane of acinar, myoepithelial and ductal cells located at cell-cell contact points.
  • Furthermore, a weak to moderate loss of expression which was related to tissue tumour subtype was seen in malignant tumours such as: adenoid cystic carcinomas; polymorphous low-grade adenocarcinomas; acinic cell carcinomas; and mucoepidermoid low-grade, epithelial-myoepithelial, lymphoepithelial and squamous low-grade carcinomas.
  • Moderate to extreme loss or alternative cytoplasmic non-functional expression were observed in cases of salivary ductal carcinoma, carcinosarcoma, myoepithelial carcinoma, oncocytic adenocarcinoma, unspecified adenocarcinoma and squamous high-grade carcinomas.
  • CONCLUSION: This study suggests a direct association of E-cadherin expression with neoplastic histologic phenotype, which is lost in the more undifferentiated and invasive epithelial salivary gland tumours.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Ductal / chemistry. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenolymphoma / chemistry. Adenoma / chemistry. Adenoma, Pleomorphic / chemistry. Humans. Immunohistochemistry / methods. Salivary Gland Diseases / metabolism. Salivary Glands / chemistry

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623973.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


13. Chijiwa H, Sakamoto K, Umeno H, Nakashima T, Suzuki G, Hayafuchi N: Minor salivary gland carcinomas of oral cavity and oropharynx. J Laryngol Otol Suppl; 2009;(31):52-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minor salivary gland carcinomas of oral cavity and oropharynx.
  • This paper reviews 22 cases of minor salivary gland carcinoma of the oral cavity or oropharynx which were treated at Kurume University Hospital between 1976 and 2005.
  • Minor salivary gland carcinoma was observed in eight of 362 patients with cancer of the oral cavity (2 per cent), and in 14 of 275 patients with cancer of the oropharynx (5 per cent).
  • The five-year and 10-year survival rates of patients with oropharyngeal minor salivary gland carcinoma were 90 per cent.
  • No statistically significant difference was observed between survival rates for oropharyngeal minor salivary gland carcinoma and for oropharyngeal squamous cell carcinoma (p = 0.06).
  • The five- and 10-year survival rates of patients with oral cavity minor salivary gland carcinoma were 75 and 37 per cent, respectively.
  • No statistically significant difference was observed between survival rates for oral cavity minor salivary gland carcinoma and oral cavity squamous cell carcinoma.Patients' survival results correlated well with the clinical stage of their lesions.
  • Adjuvant therapy is recommended for patients with grade III adenoid cystic carcinoma with perineural infiltration or intravascular infiltration.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Oropharyngeal Neoplasms / mortality. Salivary Gland Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460205.001).
  • [ISSN] 0144-2945
  • [Journal-full-title] The Journal of laryngology and otology. Supplement
  • [ISO-abbreviation] J Laryngol Otol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Abu-Ali S, Sugiura T, Takahashi M, Shiratsuchi T, Ikari T, Seki K, Hiraki A, Matsuki R, Shirasuna K: Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells. J Cell Physiol; 2005 May;203(2):410-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells.
  • Adenoid cystic carcinoma (AdCC) cell lines (ACCS and ACCT) showed higher migration responses and adhesion to the extracellular matrix (ECM), especially types I and IV collagen, than did the oral squamous cell carcinoma (SCC) lines (NA and TF).
  • Moreover, AdCC cell lines expressed higher surface levels of urokinase-type plasminogen activator receptor (uPAR) than did SCC cell lines.
  • When AdCC cells were plated on collagen, the surface level of uPAR was increased, and numerous focal adhesions consisting of uPAR, vinculin, and paxillin were assembled; whereas collagen-stimulated SCC cell counterparts or AdCC cells plated on other types of ECM, such as fibronectin, failed to assemble such definite focal adhesions.
  • In order to elucidate the association of uPAR with collagen-induced events, an ACCS-AS cell line transfected with a vector expressing antisense uPAR RNA was established and shown to have reduced uPAR (about 10% that of parental ACCS at both the protein and mRNA levels).
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Cell Movement / physiology. Focal Adhesions / metabolism. Neoplasm Invasiveness / physiopathology. Receptors, Cell Surface / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Collagen Type I / metabolism. Collagen Type I / pharmacology. Collagen Type IV / metabolism. Collagen Type IV / pharmacology. Cytoskeletal Proteins / metabolism. Extracellular Matrix Proteins / metabolism. Extracellular Matrix Proteins / pharmacology. Humans. Integrin alpha2 / metabolism. Paxillin. Phosphoproteins / metabolism. RNA, Antisense. Receptors, Urokinase Plasminogen Activator. Vinculin / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15521066.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Collagen Type IV; 0 / Cytoskeletal Proteins; 0 / Extracellular Matrix Proteins; 0 / Integrin alpha2; 0 / PLAUR protein, human; 0 / PXN protein, human; 0 / Paxillin; 0 / Phosphoproteins; 0 / RNA, Antisense; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 125361-02-6 / Vinculin
  •  go-up   go-down


15. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Other diagnostic considerations include adenoid cystic carcinoma and basaloid squamous carcinoma.
  • Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • Radiotherapy has been proposed for lesions in the minor salivary glands because of the higher likelihood of vascular and neural invasion and for those that are diffusely infiltrative.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Otsuka H, Graham MM, Kogame M, Nishitani H: The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med; 2005 Dec;19(8):691-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of FDG-PET in the management of patients with salivary gland malignancy.
  • OBJECTIVE: The aim of this study was to evaluate the impact of FDG-PET in the management of patients with salivary gland malignancy.
  • PATIENTS AND METHODS: We performed 45 FDG PET studies in 31 patients with salivary malignant tumors, using PET (33 studies) and PET/CT (12 studies).
  • Histology consisted of 8 adenocarcinomas, 8 squamous cell carcinomas, 4 adenoid cystic carcinomas, 4 carcinoma ex pleomorphic adenomas, 2 mucoepidermoid carcinomas, 2 poorly differentiated carcinomas, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma and 1 melanoma.
  • RESULTS: In the initial staging group, all 12 primary lesions (100%) showed positive FDG uptake (5 squamous cell carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 carcinoma ex pleomorphic adenoma, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma).
  • CONCLUSION: This study shows that FDG PET has a significant impact on the management of patients with salivary malignant tumors in both the initial staging and restaging.
  • [MeSH-major] Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Salivary Gland Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444995.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Seethala RR, Hunt JL, Baloch ZW, Livolsi VA, Leon Barnes E: Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol; 2007 Nov;31(11):1683-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature.
  • High-grade transformation of adenoid cystic carcinoma (ACC) (previously referred to as dedifferentiation) is a rare phenomenon that does not fit into the traditional ACC grading schemes.
  • The most common morphologies for the high-grade component were poorly differentiated cribriform adenocarcinoma and solid undifferentiated carcinoma.
  • ACC-high-grade transformation is a highly aggressive salivary gland tumor with a variety of histologic patterns.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Papillary / pathology. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Cell Proliferation. Cyclin D. Cyclins / analysis. Female. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Lymph Nodes / pathology. Male. Middle Aged. Mitotic Index. Necrosis. Neoplasm Invasiveness. Neoplasm Staging. Proto-Oncogene Proteins c-kit / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059225.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Cyclins; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 53
  •  go-up   go-down


18. Akrish S, Peled M, Ben-Izhak O, Nagler RM: Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol; 2009 Dec;45(12):1044-50
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis.
  • The classification system for malignant salivary gland tumors (MST) is largely dependent on its histogenesis.
  • Fifty six primary major and minor gland MST were stained with anti-cox-2 antibody and rated with a combined score that added a scale of intensity to the percentage of tumor cells that overexpressed the cox-2 protein.
  • Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%).
  • Primary squamous cell carcinoma (PSCC) was the exception.
  • Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma.
  • Strong cox-2 overexpression was noted in the epidermoid cells of MEC, abluminal duct cells surrounding the duct-like structures and ductal cells of AdC nos and salivary duct carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cyclooxygenase 2 / analysis. Salivary Gland Neoplasms / enzymology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729335.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


19. Bandyopadhyay A, Das TK, Raha K, Hati GC, Mitra PK, Dasgupta A: A study of fine needle aspiration cytology of salivary gland lesions with histopathological corroboration. J Indian Med Assoc; 2005 Jun;103(6):312-4, 316
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of fine needle aspiration cytology of salivary gland lesions with histopathological corroboration.
  • The diagnostic utility of fine needle aspiration cytology as initial work up of salivary gland enlargement was assessed in one hundred and eighty-five salivary gland specimens over three years period and corroborated with histopathology, whenever feasible.
  • All smears were evaluated according to cell size, amount of cytoplasm, cytologic atypia and presence of lymphocytes. (a) Variable cytologic appearances of pleomorphic salivary adenoma were observed. (b) Cellular pleomorphic adenoma and adenoid cystic carcinoma showed basaloid cell features. (c) Tumours with intermediate size cells and bland cytology included low grade muco-epidermoid carcinoma and cystic lesions. (d) Warthin's tumour, oncocytoma, salivary duct carcinoma and high grade muco-epidermoid carcinoma revealed large cells and abundant cytoplasm with or without atypia.
  • Malignant tumours included muco-epidermoid carcinoma (n = 5), adenoid cystic carcinoma (n = 3), acinic cell carcinoma (n = 2), adenocarcinoma (n= 2), squamous cell carcinoma (n = 1), undifferentiated carcinoma (n= 4) and malignant lymphoma (n = 1).
  • So it can be concluded that fine needle aspiration cytology can play important role in early diagnosis and subsequent therapeutic planning of salivary gland lesions.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Sialadenitis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225156.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


20. Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li J, Song L: Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer; 2010;10:495
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy.
  • The current study was to characterize the expression of SPHK1 in salivary gland carcinomas (SGC) and to investigate the association between SPHK1 expression and progression of SGC.
  • METHODS: The expression of SPHK1 was examined in 2 normal salivary gland tissues, 8 SGC tissues of various clinical stages, and 5 pairs of primary SGC and adjacent salivary gland tissues from the same patient, using real-time PCR and western blot analysis.
  • RESULTS: SPHK1 expression was found to be markedly upregulated in SGC tissues than that in the normal salivary gland tissues and paired adjacent salivary gland tissues, at both mRNA and protein levels.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Phosphotransferases (Alcohol Group Acceptor) / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands / metabolism
  • [MeSH-minor] Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Blotting, Western. Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cohort Studies. Disease Progression. Female. Gamma Rays. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucoepidermoid Tumor / genetics. Mucoepidermoid Tumor / metabolism. Mucoepidermoid Tumor / pathology. Palliative Care. Prognosis. RNA, Messenger / genetics. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Res. 2003 May;47(5):401-7 [12676514.001]
  • [Cites] Histopathology. 2003 Apr;42(4):348-56 [12653946.001]
  • [Cites] J Atheroscler Thromb. 2003;10(3):125-31 [14564080.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):914-8 [14645349.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1040-4 [15252310.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7359-69 [15314148.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] J Craniomaxillofac Surg. 1996 Jun;24(3):133-9 [8842902.001]
  • [Cites] Science. 1998 Mar 6;279(5356):1552-5 [9488656.001]
  • [Cites] Head Neck. 1999 Aug;21(5):414-9 [10402521.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3169-77 [15632208.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2526-33 [15900577.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Aug;64(8):695-705 [16106218.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1808-16 [15890687.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11667-75 [16357178.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 21;342(4):1284-90 [16516161.001]
  • [Cites] Leukemia. 2006 Jan;20(1):95-102 [16281067.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Aug;318(2):596-603 [16632640.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(19):7211-23 [16980623.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1758(12):2016-26 [16996023.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Jun;264(6):587-94 [17415578.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3661-6 [17972532.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):54-8 [18091319.001]
  • [Cites] Leukemia. 2008 May;22(5):971-9 [18401414.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3319-26 [18519759.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1393-9 [19228740.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):545-58 [10545499.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):518-23 [10649241.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):836-9 [10835516.001]
  • [Cites] Curr Biol. 2000 Nov 30;10(23):1527-30 [11114522.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):385-402 [10880336.001]
  • [Cites] J Neurochem. 2001 Mar;76(5):1573-84 [11238741.001]
  • [Cites] Laryngorhinootologie. 2001 Sep;80(9):525-9 [11555785.001]
  • [Cites] Pathol Res Pract. 2001;197(9):621-6 [11569926.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):72-80 [12069812.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1784-5 [12176575.001]
  • [Cites] Exp Cell Res. 2002 Nov 15;281(1):115-27 [12441135.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):397-407 [12728273.001]
  • (PMID = 20846391.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase
  • [Other-IDs] NLM/ PMC2949806
  •  go-up   go-down


21. Kupferman ME, de la Garza GO, Santillan AA, Williams MD, Varghese BT, Huh W, Roberts D, Weber RS: Outcomes of pediatric patients with malignancies of the major salivary glands. Ann Surg Oncol; 2010 Dec;17(12):3301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of pediatric patients with malignancies of the major salivary glands.
  • BACKGROUND: To report the outcomes and early to long term treatment complications among pediatric patients with major salivary gland malignancies treated at a single institution.
  • Patients less than 19 years of age with a diagnosis of a major salivary gland malignancy were identified at the M. D.
  • The majority of tumors arose in the parotid gland (83%), and the most common pathology was mucoepidermoid carcinoma (46%).
  • Lymphatic metastasis was identified in 37% of patients, nearly all with mucoepidermoid carcinoma.
  • CONCLUSIONS: Survival of pediatric patients with major salivary gland carcinomas is favorable.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Mucoepidermoid / therapy. Carcinoma, Squamous Cell / therapy. Salivary Gland Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585877.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Lü BJ, Zhu J, Gao L, Xie L, Xu JY, Lai MD: [Diagnostic accuracy and pitfalls in fine needle aspiration cytology of salivary glands: a study of 113 cases]. Zhonghua Bing Li Xue Za Zhi; 2005 Nov;34(11):706-10
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic accuracy and pitfalls in fine needle aspiration cytology of salivary glands: a study of 113 cases].
  • OBJECTIVE: To describe the fine needle aspiration cytology (FNAC) features of various salivary gland lesions and to analyze the respective diagnostic value and pitfalls.
  • METHODS: 113 FNAC specimens of salivary gland lesions were reviewed and correlated with clinical and histopathologic findings.
  • Cytologically, the distinction between cellular pleomorphic adenoma, adenoid cystic carcinoma and basal cell adenoma could be difficult due to their overlapping morphologic features.
  • The cytologic patterns of primary lymphoepithelial carcinoma of the parotid were indistinguishable from those of metastatic nasopharyngeal undifferentiated carcinoma.
  • The three inaccurately diagnosed cases of FNAC are, as follows: reactive lymphoid hyperplasia of lymph node mistaken as non-Hodgkin lymphoma, mucoepidermoid carcinoma diagnosed as "scanty atypical cells present" and primary lymphoepithelial carcinoma mistaken as benign lymphoepithelial lesion.
  • CONCLUSIONS: FNAC is reliable in distinguishing benign and malignant salivary gland lesions.
  • A specific cytologic diagnosis is often possible.
  • On the other hand, due to the pitfalls in cytologic diagnosis of certain salivary gland tumors, tissue biopsy for histologic examination may be necessary.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Carcinoma, Squamous Cell / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology
  • [MeSH-minor] Adenolymphoma / pathology. Adenoma / pathology. Adenoma, Pleomorphic / pathology. Adolescent. Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Adenoid Cystic / pathology. Child. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Middle Aged. Parotid Neoplasms / pathology. Retrospective Studies. Submandibular Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536312.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Boukheris H, Curtis RE, Land CE, Dores GM: Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev; 2009 Nov;18(11):2899-906
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States.
  • BACKGROUND: Carcinomas of the major salivary glands (M-SGC) comprise a morphologically diverse group of rare tumors of largely unknown cause.
  • Squamous cell (IR, 3.44) and mucoepidermoid (IR, 3.23) carcinomas occurred most frequently among males, whereas mucoepidermoid (IR, 2.67), acinic cell (IR, 1.57), and adenoid cystic (IR, 1.40) carcinomas were most common among females.
  • Mucoepidermoid, acinic cell, and adenoid cystic carcinomas predominated in females through age approximately 50 years; thereafter, IRs of acinic cell and adenoid cystic carcinomas were nearly equal among females and males, whereas IRs of mucoepidermoid carcinoma among males exceeded IRs among females (IRR, 1.57; 95% CI, 1.38-1.78).
  • Except for mucoepidermoid and adenoid cystic carcinomas, which occurred equally among all races, other subtypes had significantly lower incidence among Blacks and Asians/Pacific Islanders than among Whites.
  • Adenoid cystic carcinoma occurred equally in the submandibular and parotid glands, and other M-SGC histologic subtypes evaluated had 77% to 98% lower IRs in the submandibular gland.
  • [MeSH-major] Salivary Gland Neoplasms / classification. Salivary Gland Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1095-100 [10613342.001]
  • [Cites] Community Dent Health. 2008 Sep;25(3):148-53 [18839720.001]
  • [Cites] Oral Oncol. 2002 Sep;38(6):610-7 [12167440.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):706-13 [12167424.001]
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Afr J Med Med Sci. 2001 Mar-Jun;30(1-2):95-8 [14510160.001]
  • [Cites] Cancer. 1971 Jun;27(6):1415-8 [4325986.001]
  • [Cites] Arch Otolaryngol. 1984 Jan;110(1):45-9 [6689907.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1854-9 [6478421.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Biometrics. 1985 Jun;41(2):361-72 [4027319.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Aust N Z J Surg. 1987 Jan;57(1):23-6 [3472508.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Oct;116(10):1163-6 [2206501.001]
  • [Cites] Int J Epidemiol. 1991 Sep;20(3):628-33 [1955246.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):369-77 [1317882.001]
  • [Cites] East Afr Med J. 1992 Sep;69(9):525-30 [1286637.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):147-53 [8000993.001]
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Radiat Res. 1996 Jul;146(1):28-36 [8677295.001]
  • [Cites] Oral Oncol. 1997 May;33(3):169-76 [9307725.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Feb;118(2):195-8 [9482552.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):27-33 [10334639.001]
  • [Cites] Epidemiology. 1999 Sep;10(5):528-30 [10468426.001]
  • [Cites] Cancer. 1953 Nov;6(6):1065-133 [13106826.001]
  • [Cites] Acta Otolaryngol. 2005 Feb;125(2):207-14 [15880955.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Head Neck. 2006 Jul;28(7):626-32 [16475198.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Dec;135(6):844-8 [17141071.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • [Cites] Cancer. 2008 May 1;112(9):1974-82 [18361448.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):768-70 [10622505.001]
  • (PMID = 19861510.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010183-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS144622; NLM/ PMC2779732
  •  go-up   go-down


24. Roh JL, Choi SH, Lee SW, Cho KJ, Nam SY, Kim SY: Carcinomas arising in the submandibular gland: high propensity for systemic failure. J Surg Oncol; 2008 May 1;97(6):533-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomas arising in the submandibular gland: high propensity for systemic failure.
  • BACKGROUND: Cancers of the submandibular gland are uncommon and only a few small series have reported patient survival and prognosis.
  • METHODS: We examined the treatment outcomes of 62 patients with surgically treated submandibular gland carcinomas.
  • RESULTS: Of the 62 submandibular gland carcinomas, 19 were adenoid cystic, 11 were mucoepidermoid, and 10 were salivary duct carcinomas, and 8 were carcinomas in pleomorphic adenoma.
  • CONCLUSIONS: Despite effective locoregional treatment, approximately one-third of patients with submandibular gland carcinomas may fail systemically, resulting in poor survival.
  • [MeSH-major] Neoplasm Recurrence, Local. Submandibular Gland Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adolescent. Adult. Aged. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Mucoepidermoid / mortality. Carcinoma, Mucoepidermoid / radiotherapy. Carcinoma, Mucoepidermoid / surgery. Carcinoma, Mucoepidermoid / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18286522.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. González-García R, Nam-Cha SH, Muñoz-Guerra MF, Gamallo-Amat C: Basal cell adenoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E206-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland. Case report and review of the literature.
  • Basal cell adenoma of the salivary glands is an uncommon type of monomorphous adenoma.
  • Its most frequent location is the parotid gland.
  • Due to prognostic implications, differential diagnosis with basal cell adenocarcinoma, adenoid cystic carcinoma and basaloid squamous cell carcinoma is mandatory.
  • We describe a case of basal cell adenoma of the parotid gland.
  • We also review the literature and discuss the diagnosis and management of this rare entity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505803.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


26. Zhang S, Bao R, Bagby J, Abreo F: Fine needle aspiration of salivary glands: 5-year experience from a single academic center. Acta Cytol; 2009 Jul-Aug;53(4):375-82
MedlinePlus Health Information. consumer health - Salivary Gland Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of salivary glands: 5-year experience from a single academic center.
  • OBJECTIVE: To investigate 5 years' experience with fine needle aspiration (FNA) of salivary glands at a single academic center.
  • STUDY DESIGN: A total of 191 salivary gland FNAs were performed at Louisiana State University Health Science Center from 2003 to 2007, and all were done on major salivary glands except for 1 case.
  • There were 5 false negatives: 2 adenoid cystic carcinomas, 1 acinic cell carcinoma, 1 polymorphous low grade adenocarcinoma and 1 metastatic basaloid squamous cell carcinoma.
  • The only false positive was a pleomorphic adenoma misdiagnosed as adenoid cystic carcinoma.
  • The overall accuracy in distinguishing benign from malignant lesions was 79.1%, and the sensitivity for salivary neoplasia was 89.4%.
  • CONCLUSION: Our results are consistent with the literature that salivary gland FNA has good sensitivity, specificity and accuracy in the diagnosis of salivary neoplasms.
  • [MeSH-major] Biopsy, Fine-Needle. Salivary Gland Diseases / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697720.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Chen AM, Garcia J, Lee NY, Bucci MK, Eisele DW: Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):988-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation?
  • PURPOSE: To evaluate the incidence of nodal relapses from carcinomas of the salivary glands among patients with clinically negative necks in an attempt to determine the potential utility of elective neck irradiation (ENI).
  • METHODS AND MATERIALS: Between 1960 and 2004, 251 patients with clinically N0 carcinomas of the salivary glands were treated with surgery and postoperative radiation therapy.
  • Histology was: adenoid cystic (84 patients), mucoepidermoid (60 patients), adenocarcinoma (58 patients), acinic cell (21 patients), undifferentiated (11 patients), carcinoma ex pleomorphic adenoma (7 patients), squamous cell (7 patients), and salivary duct carcinoma (3 patients); 131 patients (52%) had ENI.
  • The highest crude rates of nodal relapse among those treated without ENI were found in patients with squamous cell carcinoma (67%), undifferentiated carcinoma (50%), adenocarcinoma (34%), and mucoepidermoid carcinoma (29%).
  • There were no nodal failures observed among patients with adenoid cystic or acinic cell histology.
  • [MeSH-major] Carcinoma / secondary. Lymphatic Irradiation. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234357.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Eslami B, Rahimi H, Rahimi F, Khiavi MM, Ebadifar A: Diagnostic value of silver nitrate staining for nucleolar organizer regions in selected head and neck tumors. J Cancer Res Ther; 2006 Jul-Sep;2(3):129-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study is aimed to assess the usefulness of silver nitrate staining of nucleolar organizer regions (NORs) as a quantitative criterion for the diagnosis of selected head and neck tumors.
  • The samples consisted of 21 squamous cell carcinoma (SCC) of larynx, 28 SCC of oral mucosa and 36 samples of most common salivary gland tumors.
  • RESULTS: A significant difference was seen in the number of AgNOR dots between oral and laryngeal SCC with surrounding dysplastic and normal tissues (P < 0.001) and also between mucoepidermoid carcinoma and adenoid cystic carcinoma with pleomorphic adenoma and normal salivary gland tissue (P < 0.001).
  • CONCLUSION: The silver nitrate staining for NORs is a useful method for aiding the diagnosis of malignant and dysplastic mucosal lesions and also malignant and benign salivary gland tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Nucleolus Organizer Region / metabolism. Silver Staining
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Humans. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998691.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


29. Lin C, Li J, Lu N: [Analysis of 2161 cases of neoplasm in oral maxillofacial region in Xinjiang]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Sep;45(9):553-5
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinoma constituted the majority of the malignant tumors.
  • The most common malignant tumors of salivary gland were adenoid cystic carcinoma.
  • The most common sites of malignant tumors were tongue, lip, parotiod gland and buccal mucosa.
  • Adenoid cystic carcinoma was more common than other salivary originated tumors.
  • [MeSH-minor] Adenolymphoma. Adenoma, Pleomorphic. Ameloblastoma. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. China / epidemiology. Face. Humans. Incidence. Mouth Mucosa. Odontogenic Tumors. Retrospective Studies. Salivary Gland Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122451.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Guo XL, Wei FC, Sun SZ: [Clinical study of oral and maxillofacial malignancies associated with multiple primary malignant neoplasms]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2006 Feb;24(1):42-4
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinical characteristics, diagnosis and treatment strategy of oral and maxillofacial malignancies in multiple primary malignant neoplasms (MPMNs).
  • Among the 44 cases, there were 24 cases in alimentary and respiratory tract such as oral, pharynx, esophagus, stomach and lung, and 10 cases in salivary gland, breast and female reproductive system.
  • There were 25 cases malignant neoplasms in oral and maxillofacial region where squamous cell carcinoma was the most common pathologic type, secondly adenoid cystic carcinoma.
  • In oral and maxillofacial region, MPMNs were often found in tongue, parotid and submandibular gland, buccal mucosa and gingival.
  • CONCLUSION: Tongue and salivary gland were the common locations with MPMNs, and they were closely associated with alimentary and respiratory tract.
  • Regular follow-up, early detection, early diagnosis, active and effective treatment can help to improve the survival quality of MPMNs patients.
  • [MeSH-major] Carcinoma, Adenoid Cystic. Carcinoma, Squamous Cell. Mouth Neoplasms. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541654.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Le Tourneau C: [Molecularly targeted therapy in head and neck cancer]. Bull Cancer; 2010 Dec;97(12):1453-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck squamous cell carcinomas (HNSCC) were indeed one of the first tumor types to get a molecularly targeted agent approved (cetuximab, a monoclonal antibody targeting EGFR), not only in the recurrent or metastatic setting but also in the locally advanced setting.
  • This article summarizes recent data on molecularly targeted agents in most frequent head and neck cancers including HNSCC, nasopharyngeal carcinoma and adenoid cystic carcinoma of salivary glands.
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal, Humanized. Carcinoma, Adenoid Cystic / drug therapy. Cetuximab. Cisplatin / therapeutic use. Combined Modality Therapy / methods. Humans. Nasopharyngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Protein Kinase Inhibitors / therapeutic use. Randomized Controlled Trials as Topic. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21134823.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; Nasopharyngeal carcinoma
  •  go-up   go-down


32. Kazakov DV, Zelger B, Rütten A, Vazmitel M, Spagnolo DV, Kacerovska D, Vanecek T, Grossmann P, Sima R, Grayson W, Calonje E, Koren J, Mukensnabl P, Danis D, Michal M: Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. Am J Surg Pathol; 2009 May;33(5):705-19
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) salivary gland type basal cell adenocarcinoma-like pattern, low-grade (BCAC-LG);.
  • 2) salivary gland type basal cell adenocarcinoma-like pattern, high-grade (BCAC-HG);.
  • 3) invasive adenocarcinoma, not otherwise specified (IAC-NOS); and 4) sarcomatoid (metaplastic) carcinoma.
  • Cases harboring a sarcomatoid carcinoma featured a malignant epithelial component composed of varying combinations of BCAC-HG, BCAC-LG, IAC-NOS, or squamous cell carcinoma, whereas the sarcomatoid component appeared as either a pleomorphic or spindle-cell sarcoma.
  • Patients with sarcomatoid carcinoma had a relatively good survival.
  • Given the morphologic diversity and complexity of the neoplasms in question, we propose using a more specific terminology with the precise description of the neoplasm components, rather than generic and less informative terms such as "spiradenocarcinoma" or "carcinoma ex cylindroma. "
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Salivary Gland Neoplasms / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Australia. Carcinoma, Skin Appendage / pathology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Chromosomes, Human, Pair 16. Europe. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Metaplasia. Middle Aged. Mutation. Neoplasm Invasiveness. South Africa. Syndrome. Treatment Outcome. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Malignant cylindroma.
  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194280.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


33. Gil Z, Carlson DL, Gupta A, Lee N, Hoppe B, Shah JP, Kraus DH: Patterns and incidence of neural invasion in patients with cancers of the paranasal sinuses. Arch Otolaryngol Head Neck Surg; 2009 Feb;135(2):173-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal undifferentiated, adenoid cystic, and squamous cell carcinoma had a high propensity for NI, whereas melanoma and sarcoma rarely invaded nerves.
  • Patients with NI were more likely to undergo adjuvant radiotherapy (P = .003), which significantly improved survival in patients with minor salivary gland carcinomas (P = .04).
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / pathology. Child. Female. Humans. Male. Melanoma / pathology. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221246.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Chang SM, Xing RD, Zhang FM, Duan YQ: Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy. Oral Dis; 2009 Nov;15(8):570-2
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the levels of serum sCD44v6 in patients with oral cancer and evaluate the value of serum sCD44v6 in adjuvant diagnosis, staging and monitoring treatment response in these patients.
  • One week after treatment, venous blood was collected once again in 60 patients with oral and maxillofacial squamous cell carcinoma (OSCC).
  • The levels of serum sCD44v6 in patients with OSCC and salivary carcinoma showed no difference with those in control group (P > 0.05).
  • CONCLUSION: The possible roles of CD44v6 in the diagnosis of oral and maxillofacial malignancy deserve further elucidation and evaluation.
  • [MeSH-major] Antigens, CD44 / blood. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Head and Neck Neoplasms / blood. Mouth Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / blood. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / blood. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / surgery. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Reference Values. Salivary Gland Neoplasms / blood. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563418.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen
  •  go-up   go-down


35. Jereczek-Fossa BA, Krengli M, Orecchia R: Particle beam radiotherapy for head and neck tumors: radiobiological basis and clinical experience. Head Neck; 2006 Aug;28(8):750-60
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is now well accepted that there are certain indications for using proton therapy for skull base tumors (chordoma and chondrosarcoma), paranasal sinus carcinomas, selected nasopharyngeal tumors, and neutron/ion therapy for salivary gland carcinomas (in particular, adenoid cystic tumors).
  • Its viability in other cases, such as locally advanced squamous cell carcinoma, melanoma, soft tissue sarcoma, and bone sarcoma, is still under investigation.
  • [MeSH-minor] Chordoma / radiotherapy. Humans. Melanoma / radiotherapy. Nose Neoplasms / radiotherapy. Pharyngeal Neoplasms / radiotherapy. Radiobiology. Radiotherapy Dosage. Salivary Gland Neoplasms / radiotherapy. Skin Neoplasms / radiotherapy. Skull Base Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16804876.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


36. Doshi DV, Tripathi U, Dave RI, Pandya SJ, Shukla HK, Parikh BC: Rare tumors of sinonasal track. Indian J Otolaryngol Head Neck Surg; 2010 Jun;62(2):111-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Eighty-nine cases of the non-squamous cell malignancy were identified.
  • In this study, we found minor salivary gland tumor in 31 patients, sarcoma in 19 patients, spindle cell carcinoma (SpCC) in 19 patients, undifferentiated carcinoma in 9 patients, lymphoma in 6 patients and melanoma in 3 patients.
  • Adenoid cystic carcinoma exhibited the best survival rate (3 years survival rate was 77%), whereas melanoma and undifferentiated carcinoma exhibited poor survivals (1 year survival was 25% and 33%, respectively and 3 years survival rate is 0%).
  • CONCLUSIONS: Adenoid cystic carcinoma is the most common squamous cell carcinoma (SCC) of the sinonasal track.
  • Survival for the patients with undifferentiated carcinoma and melanoma involving the sinonasal track is poor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;419(3):177-82 [1718079.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):657-61 [1730116.001]
  • [Cites] Br J Oral Maxillofac Surg. 1990 Apr;28(2):114-6 [2337562.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):967-71 [2808058.001]
  • [Cites] Laryngoscope. 1989 Feb;99(2):143-50 [2913425.001]
  • [Cites] Minerva Stomatol. 1993 Jan-Feb;42(1-2):49-56 [8510619.001]
  • [Cites] J Periodontol. 2004 Dec;75(12):1724-7 [15732878.001]
  • [Cites] J Periodontol. 2007 Sep;78(9):1839-45 [17760557.001]
  • [Cites] Cancer. 1967 Mar;20(3):377-91 [5228026.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Feb;83(2):265-71 [9117760.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 1999 Apr;100(1):34-7 [10444768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):541-9 [10701732.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):315-9 [11182047.001]
  • [Cites] J Postgrad Med. 2004 Jul-Sep;50(3):200-1 [15377806.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Jul;64(7):1114-20 [16781345.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Nov;263(11):996-1000 [16819660.001]
  • (PMID = 23120695.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450295
  • [Keywords] NOTNLM ; Clinical features / Rare tumor / Sino nasal
  •  go-up   go-down


37. Das S, Kirsch CF: Imaging of lumps and bumps in the nose: a review of sinonasal tumours. Cancer Imaging; 2005;5:167-77

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although sinus tumours are rare, they portend a poor prognosis, often due to advanced disease at diagnosis.
  • Malignant neoplasms reviewed include squamous cell carcinoma, the minor salivary gland tumour, adenoid cystic carcinoma, adenocarcinoma, melanoma, lymphoma, and olfactory neuroblastoma (esthesioneuroblastoma).
  • [MeSH-major] Paranasal Sinus Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] International Cancer Imaging Society.
  • [Cites] Neurochirurgie. 2001 Dec;47(6):542-51 [11915613.001]
  • [Cites] Zhonghua Er Bi Yan Hou Ke Za Zhi. 1998 Dec;33(6):358-60 [11938850.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Aug;128(8):928-35 [12162773.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Am J Rhinol. 2002 Jul-Aug;16(4):221-7 [12222948.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1089-94 [12419436.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1998 Feb;23(1):27-33 [9563662.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S12-7 [9849403.001]
  • [Cites] Am J Rhinol. 1998 Nov-Dec;12(6):393-8 [9883294.001]
  • [Cites] Am J Rhinol. 1999 Mar-Apr;13(2):111-6 [10219439.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Dec;12(6):495-9 [15548906.001]
  • [Cites] Head Neck. 2005 May;27(5):370-5 [15714475.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):508-13 [6885504.001]
  • [Cites] Am J Surg. 1983 Oct;146(4):521-5 [6312826.001]
  • [Cites] Am J Med. 1986 Nov;81(5):911-6 [3776995.001]
  • [Cites] Head Neck Surg. 1979 Nov-Dec;2(2):119-28 [233745.001]
  • [Cites] Laryngoscope. 1987 Nov;97(11):1319-25 [2823033.001]
  • [Cites] Laryngoscope. 1988 Feb;98(2):170-5 [3339927.001]
  • [Cites] Zentralbl Allg Pathol. 1988;134(4-5):409-22 [2849264.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2002 Nov;119(5):271-80 [12464852.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Jan;67(1):59-65 [12560151.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):594-611 [12717245.001]
  • [Cites] Rhinology. 2003 Jun;41(2):122-4 [12868380.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):237-8 [12918561.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] Laryngoscope. 2004 Jan;114(1):106-12 [14710004.001]
  • [Cites] Head Neck. 2004 Jan;26(1):89-93 [14724912.001]
  • [Cites] Laryngoscope. 2004 Feb;114(2):193-200 [14755188.001]
  • [Cites] Acta Neurochir (Wien). 2004 Feb;146(2):179-82 [14963753.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2003;124(4):235-41 [15038566.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Am J Otolaryngol. 2004 May-Jun;25(3):178-85 [15124167.001]
  • [Cites] Endocr Pract. 2004 Mar-Apr;10(2):119-24 [15256328.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1467-70 [15359650.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] J Otolaryngol. 1977 Oct;6(5):412-22 [926224.001]
  • [Cites] J Otolaryngol. 1978 Aug;7(4):366-70 [691104.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1978 Sep-Oct;87(5 Pt 1):630-2 [214008.001]
  • [Cites] Arch Otolaryngol. 1981 Nov;107(11):677-82 [6271109.001]
  • [Cites] Radiology. 1989 Sep;172(3):763-6 [2772185.001]
  • [Cites] Am J Clin Oncol. 1989 Oct;12(5):387-92 [2552789.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):328-32 [2802037.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1990;52(3):187-93 [2359595.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):547-53 [1700595.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1991 Jun;16(3):309-12 [1879080.001]
  • [Cites] CA Cancer J Clin. 1992 Jan-Feb;42(1):19-38 [1728335.001]
  • [Cites] Otolaryngol Head Neck Surg. 1993 Dec;109(6):988-95 [8265198.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1281-91 [7882278.001]
  • [Cites] J Otolaryngol. 1994 Dec;23(6):430-6 [7897774.001]
  • [Cites] Ir J Med Sci. 1995 Apr-Jun;164(2):139-41 [7607840.001]
  • [Cites] Semin Diagn Pathol. 1996 May;13(2):113-7 [8734417.001]
  • [Cites] Acta Oncol. 1997;36(1):45-50 [9090965.001]
  • [Cites] J Laryngol Otol. 1997 Apr;111(4):372-5 [9176624.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1140-5 [10534159.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2000;54(1):45-51 [10719593.001]
  • [Cites] Am J Otolaryngol. 2000 May-Jun;21(3):174-8 [10834551.001]
  • [Cites] Laryngoscope. 2000 Jun;110(6):965-8 [10852514.001]
  • [Cites] Acta Otolaryngol. 2000 Jun;120(4):545-50 [10958410.001]
  • [Cites] J Laryngol Otol. 2000 Sep;114(9):727-30 [11091844.001]
  • [Cites] J Laryngol Otol. 2000 Nov;114(11):891-3 [11144847.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):141-6 [11177030.001]
  • [Cites] Acta Oncol. 2001;40(1):19-23 [11321654.001]
  • [Cites] Rhinology. 2001 Jun;39(2):66-70 [11486440.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2001;122(1):21-9 [11499229.001]
  • [Cites] Br J Plast Surg. 2001 Sep;54(6):476-80 [11513507.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(4):269-72 [11554623.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • (PMID = 16361146.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  • [Other-IDs] NLM/ PMC1665243
  •  go-up   go-down






Advertisement